ATE553113T1 - Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen - Google Patents

Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen

Info

Publication number
ATE553113T1
ATE553113T1 AT04775814T AT04775814T ATE553113T1 AT E553113 T1 ATE553113 T1 AT E553113T1 AT 04775814 T AT04775814 T AT 04775814T AT 04775814 T AT04775814 T AT 04775814T AT E553113 T1 ATE553113 T1 AT E553113T1
Authority
AT
Austria
Prior art keywords
glycoproteins
molecules
lectins
lectin
promote oligomerization
Prior art date
Application number
AT04775814T
Other languages
English (en)
Inventor
James Zabrecky
Stephen Monks
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Application granted granted Critical
Publication of ATE553113T1 publication Critical patent/ATE553113T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04775814T 2003-02-28 2004-02-27 Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen ATE553113T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45072103P 2003-02-28 2003-02-28
PCT/US2004/006047 WO2005020936A2 (en) 2003-02-28 2004-02-27 Use of lectins to promote oligomerization of glycoproteins and antigenic molecules

Publications (1)

Publication Number Publication Date
ATE553113T1 true ATE553113T1 (de) 2012-04-15

Family

ID=34272389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775814T ATE553113T1 (de) 2003-02-28 2004-02-27 Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen

Country Status (10)

Country Link
US (1) US20040258705A1 (de)
EP (1) EP1603936B1 (de)
KR (1) KR20060026004A (de)
CN (1) CN1780850A (de)
AT (1) ATE553113T1 (de)
AU (1) AU2004268497A1 (de)
CA (1) CA2517396A1 (de)
ES (1) ES2395126T3 (de)
RU (1) RU2399381C2 (de)
WO (1) WO2005020936A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040105736A (ko) * 2002-02-28 2004-12-16 안티제닉스 아이엔씨 스트레스 단백질의 올리고머화에 기초한 방법 및 산물
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
KR100755931B1 (ko) * 2003-06-11 2007-09-06 (주)두비엘 고분자형 만노스 결합형 렉틴의 대량 생산방법 및 상기방법으로 제조된 만노스 결합형 렉틴 재조합 단백질의제제화
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
AU2007305166A1 (en) * 2006-10-03 2008-04-10 University Of Southern California GRP78 as a predictor of responsiveness to therapeutic agents
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP3195868A3 (de) * 2010-10-01 2017-08-02 VentiRx Pharmaceuticals, Inc. Therapeutische verwendung eines tlr-agonisten und kombinationstherapie damit
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
RU2511545C1 (ru) * 2013-02-07 2014-04-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Способ антимикробной фотодинамической терапии острых воспалительных заболеваний гортаноглотки или их гнойных осложнений
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
HUE065073T2 (hu) * 2015-12-18 2024-04-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
EP3494991A4 (de) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
MX2019002879A (es) * 2016-09-13 2019-09-18 Centauri Therapeutics Ltd Compuestos novedosos y usos terapeuticos de los mismos.
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
EP4576103A3 (de) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigenidentifizierung mit hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
MA52363A (fr) * 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
CN108587918A (zh) * 2018-05-30 2018-09-28 昆明理工大学 一种基于兼养微藻油脂积累的方法
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041426B1 (de) * 1980-05-22 1985-11-13 Institut Pasteur Kupplungsprodukt zwischen einem Lectin und einem spezifischen Liganden, Herstellung und Anwendung auf biologischem Gebiet
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
JPH11513369A (ja) 1995-09-13 1999-11-16 フォーダム ユニバーシティー 熱ショックタンパク質を用いる治療及び予防方法
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
JP5072159B2 (ja) * 1999-10-26 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 粘膜アジュバントとしての植物レクチン

Also Published As

Publication number Publication date
WO2005020936A2 (en) 2005-03-10
EP1603936A2 (de) 2005-12-14
EP1603936A4 (de) 2007-07-25
CA2517396A1 (en) 2005-03-10
KR20060026004A (ko) 2006-03-22
AU2004268497A1 (en) 2005-03-10
ES2395126T3 (es) 2013-02-08
CN1780850A (zh) 2006-05-31
US20040258705A1 (en) 2004-12-23
EP1603936B1 (de) 2012-04-11
RU2005130173A (ru) 2006-03-10
RU2399381C2 (ru) 2010-09-20
WO2005020936A3 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
ATE553113T1 (de) Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
MX2021008800A (es) Barrera hematoencefalica humana in vitro.
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
TNSN07150A1 (en) Semi-soft c-class immunostimulatory oligonucleotides
ATE491725T1 (de) Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
TW200607863A (en) Immune modulating compounds from fungi
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE602004030541D1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
ATE520704T1 (de) Peptide für die behandlung von mit dem humanen papillomavirus (hpv) assoziiertem krebs und anderen epitheltumoren
ATE343375T1 (de) Impfstoff zur modulation zwischen t1 und t2 immunantworten
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
DE60327925D1 (de) Verwendung von löslichem fgl2 als immunosuppressivum